COVID-19 vaccine booster

GPTKB entity

Statements (64)
Predicate Object
gptkbp:instance_of gptkb:vaccine
gptkbp:administered_by gptkb:healthcare_professionals
gptkb:individuals
injection
pharmacies
clinical settings
community health centers
older adults
immunocompromised individuals
in healthcare settings
mass vaccination sites
frontline workers
mobile clinics
people with underlying health conditions
gptkbp:approves gptkb:FDA
gptkbp:available_in multiple formulations
gptkbp:can_be_combined_with other vaccines
gptkbp:contains antigens
gptkbp:developed_by gptkb:Johnson_&_Johnson
gptkb:Pfizer
gptkb:Moderna
various pharmaceutical companies
https://www.w3.org/2000/01/rdf-schema#label COVID-19 vaccine booster
gptkbp:increased antibody levels
gptkbp:is_administered_after primary vaccination
gptkbp:is_available_in gptkb:various_countries
gptkbp:is_discussed_in gptkb:literature
scientific conferences
public health forums
gptkbp:is_evaluated_by effectiveness
safety
health authorities
efficacy
long-term effects
gptkbp:is_linked_to community immunity
increased public confidence in vaccines
decreased mortality rates
reduced transmission
lower hospitalization rates
gptkbp:is_monitored_by adverse effects
gptkbp:is_part_of COVID-19 response
immunization programs
vaccination strategy
booster campaign
gptkbp:is_promoted_by government agencies
non-profit organizations
health organizations
international health organizations
gptkbp:is_promoted_through public awareness campaigns
gptkbp:is_recommended_after initial vaccination series
gptkbp:is_recommended_by gptkb:CDC
gptkbp:is_recommended_for elderly individuals
high-risk populations
gptkbp:is_studied_in clinical trials
gptkbp:is_subject_to regulatory approval
public health guidelines
gptkbp:is_targeted_at gptkb:SARS-Co_V-2
gptkbp:is_used_to combat COVID-19
gptkbp:may_be_given after a certain time period
gptkbp:provides increased immunity
gptkbp:requires initial vaccination series
gptkbp:shown_to_reduce severe illness
gptkbp:bfsParent gptkb:Bio_NTech
gptkbp:bfsLayer 5